CVKD

Cadrenal Therapeutics, Inc. (CVKD) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tecarfarin, a new-generation Vitamin K Antagonist (VKA) oral anticoagulant. The drug targets patients with rare cardiovascular conditions requiring lifelong anticoagulation, specifically those with mechanical circulatory support devices (LVAD) and end-stage kidney disease (ESKD) with atrial fibrillation. The company holds orphan drug and fast-track designations from the FDA. This report covers the quarterly period ended June 30, 2024.

Key Financial Metrics

Note: The company has no revenue. Operating expenses consist of General and Administrative (G&A) and Research and Development (R&D). There is no long-term debt outstanding.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the six months ended June 30, 2024, decreased to $4.06 million from $6.18 million in the same period in 2023. This improvement is primarily due to the absence of a $3.0 million non-cash R&D expense in 2023 related to the issuance of shares to settle an asset purchase agreement.
• Expense Composition:
  • G&A Expenses: Increased by 34% year-over-year (YTD) to $2.34 million, driven by the hiring of a Chief Operating Officer in February 2024 and increased public company compliance costs.
  • R&D Expenses: Decreased by 46% YTD to $1.88 million. Excluding the one-time $3.0 million charge in 2023, underlying R&D costs increased due to higher chemistry, manufacturing, and controls (CMC) expenses and consulting fees.
• Interest Income: Interest and dividend income increased significantly to $165,963 (YTD 2024) from $23,176 (YTD 2023), reflecting higher cash balances from the 2023 IPO and Private Placement.
• Equity Transactions: During the first half of 2024, the company issued 2,985,715 shares of common stock upon the exercise of pre-funded warrants, generating minimal cash proceeds ($298).

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. As of June 30, 2024, cash balances were approximately $5.0 million. Management projects that existing cash will not be sufficient to fund operations for the next 12 months, particularly given the capital requirements for the planned pivotal Phase 3 trial for tecarfarin.
• Financing Needs: The company intends to raise additional funds through partnering, equity, or debt financings. There is no assurance that such funding will be available on acceptable terms or at all. Failure to secure funding could force the company to delay or cease operations.
• Nasdaq Listing Compliance: The company received notice from Nasdaq in September 2023 regarding non-compliance with the minimum bid price requirement ($1.00 per share). An extension was granted until September 3, 2024. The company intends to effect a reverse stock split (approved by shareholders on July 29, 2024) to regain compliance, though there is no assurance this will be successful.
• Equity Plan Amendment: Shareholders approved an amendment to the 2022 Equity Incentive Plan to increase available shares by 2,000,000 and modify the "evergreen provision" to include shares issuable upon warrant exercise.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts or partnership discussions.
• Nasdaq Compliance: Monitor the company's progress in regaining compliance with Nasdaq Listing Rule 5550(a)(2) and the execution of the approved reverse stock split.
• Phase 3 Trial Status: Confirm the timeline and funding requirements for the initiation of patient enrollment in the pivotal Phase 3 trial for tecarfarin.
• Dilution Risk: Assess the potential dilution from future equity financings and the impact of the 4.67 million warrants currently outstanding.
• Going Concern Status: Review the explanatory paragraph in the financial statements regarding the uncertainty of the company's ability to continue operations.